Alternative dosing schedules for cetuximab: A role for biweekly administration?

Clinical Colorectal Cancer

Volumn 7, Issue 6, 2008, Pages 364-368

  Ramanathan, Ramesh K ^a,b  

^a Scottsdale Health Care   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

EGFR; FOLFIRI; Monoclonal antibody; Squamous cell carcinoma of the head and neck

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB; RITUXIMAB; TRASTUZUMAB;

ANAPHYLAXIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HALF LIFE TIME; HEAD AND NECK CANCER; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MULTIPLE CANCER; NEUTROPENIA; RASH; REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 58849115141     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.048     Document Type: Review

References (45)

1. Erbitux® (cetuximab) [package insert]: New York, NY: ImClone Systems Incorporated and Princeton, NJ: Bristol-Myers Squibb Company; 2007.
2. Sunada H, Magun BE, Mendelsohn J, et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 1986; 83:3825-9.
3. Fan Z, Lu Y, Wu X, et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269:27595-602.
4. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935-40.
5. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-65.
6. Kawaguchi Y, Kono K, Mimura K, et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120:781-7.
7. Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53:4322-8.
8. Naramura M, Gillies SD, Mendelsohn J, et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37:343-9.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78.
10. Vermorken JB, Mesia R, Vega-Villegas ME, et al. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (EXTREME). Presented at: the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL.
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory colorectal cancer. New Engl J Med 2004; 351:337-45.
12. Jonker JD, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8.
13. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-9.
14. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
15. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914-21.
16. Cartwright TH, Kuefler P, Cohn A, et al. Results of a phase II trial of cetuximab+XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer. J Clin Oncol 2006; 24(18 suppl):616s (Abstract 13502).
17. Jennis A, Polikoff J, Mitchell E, et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol 2005; 23(16 suppl):264s (Abstract 3574).
18. Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007; 18:305-10.
19. Grande C, Mel JR, Salgado M, et al. Multicenter phase II study of cetuximab and irinotecan as third line chemotherapy in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with both irinotecan and oxaliplatin regimens. J Clin Oncol 2006; 24(18 suppl):620s (Abstract 13551).
20. Borner M, Mingrone W, Koeberle D, et al. The impact of cetuximab on the capecitabine plus oxaliplatin combination in first-line treatment of metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3551).
21. Colucci G, Giuliani F, Mattioli R, et al. FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer: a phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). J Clin Oncol 2006; 24(18 suppl):160s (Abstract 3559).
22. Dakhil S, Cosgriff T, Headley D, et al. Cetuximab + FOLFOX 6 as first-line therapy for metastatic colorectal cancer (an International Oncology Network Study, I-03-002). J Clin Oncol 2006; 24(18 suppl):160s (Abstract 3557).
23. Heinemann V, Fischer Von Weikersthal L, Moosmann N, et al. Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first-line therapy for patients with metastatic colorectal cancer (CRC): preliminary results of a randomized phase II trial of the AIO CRC Study Group. J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3550).
24. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25(18 suppl):172s (Abstract 4035).
25. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
26. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based chemotherapy. J Clin Oncol 2007; 25:2171-7.
27. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study [published erratum appears in: J Clin Oncol 2006; 24:724].
28. J Clin Oncol 2005; 23:8646-54.
29. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 22:618s (Abstract 7012).
30. Butts CA, Bodkin D, Middleman EL, et al. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):394s (Abstract 7539).
31. Herbst RS, Chansky K, KellyK, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced NSCLC: final report of SWOG 0342. J Clin Oncol 2007; 25(18 suppl):395s (Abstract 7545).
32. Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23:8786-93.
33. ClinicalTrials.gov [Web site]. Cetuximab, paclitaxel, carboplatin, and bevacizumab in treating patients with advanced non-small cell lung cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00368992?term= 00368992&rank=1. Accessed: August 28, 2007.
34. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
35. Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: the 97th Annual Meeting of the American Association for Cancer Research; April 1-5, 2006; Washington, DC: Abstract #CP-1.
36. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [published erratum appears in: N Engl J Med 2007; 356:318]. N Engl J Med 2006; 355:2542-50.
37. Rituxan® (rituximab) [package insert]. South San Francisco, CA Genentech, Inc. and Cambridge, MA: Biogen Idec Inc.; September 2006.
38. Herceptin® (trastuzumab) [package insert]. South San Francisco, CA: Genentech, Inc.; November 2006.
39. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-14.
40. Tan AR, Moore DF, Hidalgo M, et al. Pharmacokinetics of cetuximab after administration of escalating dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006; 12:6517-22.
41. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-43.
42. Fracasso PM, Burris H III, Arquette MA, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13:986-93.
43. Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24(18 suppl):142s (Abstract 3085).
44. Pfeiffer P, Nielsen D, Yilmaz M, et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007; 46:697-701.
45. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK) and pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007; 25(18 suppl):172s (Abstract 4037).